Image
Group 2458.png

What is Blood Pressure Variability (BPV)?

Blood-pressure variability (BPV) is a complex phenomenon that includes short-term fluctuations occurring within a 24 h period as well as blood pressure changes over more-prolonged periods of time.1

What are the types of Blood Pressure Variability (BPV)?

Short term BPV 1

 

Image
Frame 4271 (1).png

 

Very short-term BPV (beat-by-beat) 1

Image
Frame 4271 (2).png

 

Short-term BPV (within 24 h) 1

Long term BPV 1

 

Image
Frame 4271 (3).png

 

Long-term BPV (day-by-day) 1

Image
Frame 4271 (4).png

 

Long-term BPV (visit-to-visit) 1

 

Improper dosing or titration of antihypertensive therapy (AHT), along with reduced adherence, is one of the causes of long-term blood pressure variability (BPV). 1

 

What is the clinical relevance of blood pressure variability (BPV)?

 

Image
Frame 2336.png

 

Visit-to-visit variability in Systolic blood pressure (SBP) is a strong independent predictor of stroke and coronary events.2

To learn more about the types of blood pressure variability, their mechanisms, and how each is measured, Please click here

The Smoothness Index (SI) and trough-to-peak (T/P) ratio are methods for evaluating 24-hour BP control in hypertension. SI has proven superior to T/P in assessing the homogeneity of BP reduction from antihypertensive therapy.3

BPV: Blood pressure variability.

References

  1. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nature Reviews Cardiology. 2013 Mar;10(3):143-55.

  2. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010 Mar 13;375(9718):895-905.

  3. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Manciaa G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. Journal of hypertension. 1998 Nov 1;16(11):1685-91.

Notified to Egyptian Drug Authority: ONA4998-04032026. Invalidation date: 04/03/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

Image
ONA4998_qrCode 1.png

ONA4998-01032026
04/03/2027

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting